Based on the results of that study, HER2-targeted molecular therapies acquired high relevance in the treatment of gastric cancer [12], indicating the importance of identifying which clinical and/or pathological features or molecular differences might be predictive of sensitivity or resistance to anti-HER2 therapies. The gene discussed is ERBB2; the disease is gastric cancer.